C84.06

Clinical Causes: The exact cause of mycosis fungoides is unknown, but it is believed to involve genetic mutations in T-lymphocytes, a type of immune cell. Chronic exposure to certain chemicals or environmental toxins may contribute in some cases. A familial predisposition has been suggested, although no specific genes have been conclusively linked. Immunosuppression, either due to medical treatments or other conditions, might increase vulnerability. Infections are not directly linked to mycosis fungoides but are concerns when the immune system is compromised.

Key Symptoms: Persistent patches or plaques on the skin resembling eczema or psoriasis. Itchy skin, which may be severe and persistent. Red or brown skin lesions that may ulcerate or become scalier over time. Swollen lymph nodes, especially if the disease progresses beyond the skin. In some cases, skin becomes thickened or develops tumors. Symptoms may gradually worsen over months or years, often leading to more widespread disease if untreated.

Diagnosis Path: Physical examination focusing on skin lesions and palpable lymph nodes. Skin biopsies to identify characteristic features of the lymphoma, such as atypical T-cells. Imaging studies like CT, MRI, or PET scans to assess the extent of lymph node involvement and identify intrapelvic lymphadenopathy. Lymph node biopsy for histopathological confirmation if enlarged nodes are detected. Blood tests may be performed to evaluate overall health and immune function.

Treatment Protocols: Topical therapies such as corticosteroids, chemotherapy agents, or skin-directed radiation for early skin lesions. Phototherapy techniques like PUVA (psoralen plus ultraviolet A) to reduce skin disease activity. Systemic therapies including chemotherapy, immunotherapy, or targeted agents for advanced disease or lymph node involvement. Radiation therapy targeted at affected lymph nodes to control localized disease. Biologic agents may be considered to modulate the immune response. In some cases, stem cell transplants could be an option for extensive or refractory disease.